Geovax Labs Inc (OTCMKTS:GOVX) has been working towards developing human vaccines innovatively against the deadly viruses – Marburg and Ebola. The biotech company has also used its expertise to find solutions to treat against HIV using innovative novel technology. The company has taken a great stride forward in announcing that it has appointed Randal D. Chase, an eminent vaccine expert and Ph.D. aged 65 years to its board as one of the directors. With this appointment, GOVX now has 6 members in its board; amongst them 4 are independent.
Dr. Chase has been an active business consultant and advisor to myriad companies who deal in life science support segments. He had served tenure of 5 years between 2006 and 2011 as the CEO and President of a clinical biotech company called Immunovaccine, Inc – primarily associated with developing innovative vaccines to treat cancer and such other infectious diseases.
He has also been a former President with a wide range of companies like Shire Biologics, Quadra Logic Technologies Inc, Pasteur Merieux Connaught and North American Vaccine. In his earlier days, he had worked and created a paradigm shift with his intellect and knowhow in companies like Glaxo Pharmaceuticals and Bristol Myers.
Premise Of Erudite Dr. Chase’s Knowhow
Dr. Chase has been Chairman of Mediago, Inc’s board before it was sold out to Mitsubishi Tanabe Pharma Corporation sometime in 2013. Currently, he is the Chairman designate at Medimabs, Inc which is a private corporation that deals in developing antibodies.
Dr. Chase has done Bachelor of Sciences (Biochemistry) from the esteemed Bishop’s University, Senior Executive Program at London Business School and Ph.D. from University of British Columbia in Biochemistry. After his doctorate, Dr. Chase completed his fellowship from McArdle Cancer Institute that comes under University of Wisconsin.
The Chairman at Geovax Labs Inc (OTCMKTS:GOVX), David Dodd commented that Dr. Chase would add value and expertise to the GeoVax family with his experience and knowhow on business expansion, holistic development and noticeable management.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: